BioRestorative Therapies (BRTX) investor relations material

Company overview and platform

• Clinical-stage regenerative medicine company focused on cell-based therapies for spine disorders, metabolic disease, and regenerative aesthetics.

• Proprietary platforms include BRTX-100 for chronic lumbar disc disease, ThermoStem for metabolic disorders, and BioCosmeceuticals for skin health.

• Integrated CGMP ISO-7 biologics manufacturing facility supports clinical and commercial production.

Clinical pipeline and programs

• BRTX-100 is in late-stage Phase 2 for chronic lumbar disc disease, with FDA Fast Track designation and topline data expected in spring 2027.

• ThermoStem is a preclinical brown adipose-derived stem cell platform targeting obesity and Type 2 diabetes, with proof-of-concept in animal models.

• BioCosmeceuticals platform commercializes secretome-derived skincare products for professional and at-home use.

Market opportunity and unmet needs

• 64.5 million U.S. adults suffer from chronic lower back pain, with $40 billion spent annually on surgeries.

• Global medical aesthetics market exceeds $35 billion, with regenerative products becoming the new standard.

• Current treatments for lumbar disc disease are costly, invasive, and often have high recurrence rates.